AvertD is a physician-ordered test intended for use prior to a first prescription of oral opioids to treat acute pain. AvertD test results provide personalized genetic risk information for Opioid Use Disorder (OUD) to support more informed decision-making when short-term use of prescription oral opioids is being considered, such as after elective surgeries like orthopedic surgery and dental procedures.

Because genetics is only one of many known factors associated with increased risk for OUD, AvertD test results should always be used in conjunction with a complete clinical evaluation to determine the appropriateness of prescription oral opioids for acute pain management.

Patients scheduled for a procedure where oral opioids may be prescribed to manage acute pain (pain expected to last <30 days) should consider taking the AvertD test prior to their procedure. Examples include elective surgeries like a knee replacement, dental procedures like a wisdom tooth removal, or a childbirth-related surgery such as a c-section. Patients and their doctors may benefit from better understanding their genetic risk for opioid addiction prior to these procedures to better inform their decisions about how to manage acute pain after.

The DNA sample is collected via a simple cheek swab by a healthcare professional using our DNA collection kit. The collection kit will include detailed instructions on how to collect, package, and ship the sample back to SOLVD Health at no charge.

The collection kit will include a return shipping label and detailed instructions on how to collect, package, and ship the sample back to SOLVD Health at no charge.

AvertD analyzes 15 genetic markers involved in the brain reward pathways associated with addiction to identify if a patient may have an elevated genetic risk for Opioid Use Disorder (OUD). A gene is a portion of DNA that determines a certain trait. An allele is a specific form of a gene. Alleles are responsible for the variations in which a given trait can be expressed. Below are the 15 genetic markers analyzed by AvertD.

AvertD was clinically validated through a blinded, multi-center, longitudinal study evaluating patients after their initial exposure to prescription oral opioids for 4 to 30 days (n=385). They were evaluated at least one year post-exposure. The study design allowed for random representative sampling mirroring adults in the U.S. prescribed oral opioids.

In the study, AvertD demonstrated 82% sensitivity (how often the test indicated Elevated Genetic Risk in patients who developed OUD) and 80% specificity (how often the test indicated Non-Elevated Genetic Risk in patients who did not develop OUD).¹ There were no statistically significant differences in clinical performance observed based on gender, age, length of follow-up from opioid exposure, or ethnicity. In addition, patients with an Elevated Genetic Risk were shown to be 18x more likely to develop OUD than patients with a Non-Elevated Genetic Risk.¹

Request a copy of the study

The AvertD result report will be made available to the ordering provider within 3 to 5 business days of the sample being received at our lab, often sooner.

When the AvertD result report is ready, the ordering healthcare provider will receive an email notification from SOLVD Health. This email notification will prompt them to sign in to SOLVD Health’s secure provider portal to view and print the result report, which they can then share and review with their patient.

Based on the clinical validation study, patients with an Elevated Genetic Risk are 18x more likely to develop Opioid Use Disorder (OUD) than patients with a Non-Elevated Genetic Risk.¹ If a patient is identified as having an Elevated Genetic Risk, the provider and the patient may wish to explore alternative pain management options to minimize or avoid use of opioids. An Elevated Genetic Risk result does not mean you currently have or will develop OUD.

Because genetics is only one of many known factors associated with increased risk for OUD, the AvertD result report should always be used in conjunction with a complete clinical evaluation to determine the appropriateness of oral opioids in an acute pain management plan.

To view Clinical Guidance for Selected Common Acute Pain Conditions from the Centers for Disease Control and Prevention (CDC), please visit https://www.cdc.gov/acute-pain/index.html.

Based on the clinical validation study, patients with a Non-Elevated Genetic Risk are 18x less likely to develop OUD than patients with an Elevated Genetic Risk.¹ If a patient is identified as having a Non-Elevated Genetic Risk, existing federal, state, and medical specialty guidelines should still be followed to ensure safe and effective opioid prescribing. A Non-Elevated Genetic Risk result does not mean you do not currently have OUD or that you will not develop OUD.

Because genetics is only one of many known factors associated with increased risk for OUD, the AvertD result report should always be used in conjunction with a complete clinical evaluation to determine the appropriateness of oral opioids in an acute pain management plan.

To view Clinical Guidance for Selected Common Acute Pain Conditions from the Centers for Disease Control and Prevention (CDC), please visit https://www.cdc.gov/acute-pain/index.html.

You and your healthcare provider will review your result and discuss what your result means for your acute pain management plan. Together, you will decide what your acute pain management plan will be. This plan may or may not include prescription oral opioids. If you are prescribed oral opioids, be sure to only take them as prescribed by your doctor. If you have leftover pills, you can learn how to dispose of them properly and safely by visiting https://www.fda.gov/consumers/consumer-updates/where-and-how-dispose-unused-medicines.

Depending on the patient’s insurance, their maximum out-of-pocket cost may vary. If coverage is denied or only part of the test is covered, SOLVD Health may appeal the decision on behalf of the patient. For details about coverage, please contact the patient’s insurance company. If the patient’s insurance does not pay for the test, the patient will be billed directly for $199.

SOLVD Health will submit the claim to the patient’s insurance.